Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Leleu

Showing results (1-10 of 371) with videos related to

Pageof 38
Sort By:
Blood|October 4, 2014
A key to the quest?Xavier Leleu
Thrombosis Research|October 3, 2012
Thrombosis in myeloma treated with IMiDsXavier Leleu
The Lancet. Oncology|September 7, 2013
New hope for relapsed and refractory multiple myelomaXavier Leleu
The Lancet. Haematology|April 1, 2016
Multiple myeloma: the puzzle is finally completedXavier Leleu
Faculty Reviews|October 13, 2022
Recent advances in the treatment of multiple myeloma: a brief reviewArthur Bobin, Xavier Leleu
Cancers|October 23, 2021
Relapsed/Refractory Multiple Myeloma in 2020/2021 and BeyondKlaus Podar, Xavier Leleu
Blood|February 27, 2025
Novel interferon-based antimyeloma activityArthur Bobin, Xavier Leleu
Blood|January 24, 2023
How I treat multiple myeloma in geriatric patientsThierry Facon, Xavier Leleu, Salomon Manier
Bulletin Du Cancer|August 6, 2022
[New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy]Aurélia Chacon, Arthur Bobin, Xavier Leleu
Cancers|April 13, 2023
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple MyelomaAurelia Chacon, Xavier Leleu, Arthur Bobin
Pageof 38

Showing results (1-10 of 371) with videos related to

Sort By:
Pageof 38
Blood|October 4, 2014
A key to the quest?Xavier Leleu
Thrombosis Research|October 3, 2012
Thrombosis in myeloma treated with IMiDsXavier Leleu
The Lancet. Oncology|September 7, 2013
New hope for relapsed and refractory multiple myelomaXavier Leleu
The Lancet. Haematology|April 1, 2016
Multiple myeloma: the puzzle is finally completedXavier Leleu
Faculty Reviews|October 13, 2022
Recent advances in the treatment of multiple myeloma: a brief reviewArthur Bobin, Xavier Leleu
Cancers|October 23, 2021
Relapsed/Refractory Multiple Myeloma in 2020/2021 and BeyondKlaus Podar, Xavier Leleu
Blood|February 27, 2025
Novel interferon-based antimyeloma activityArthur Bobin, Xavier Leleu
Blood|January 24, 2023
How I treat multiple myeloma in geriatric patientsThierry Facon, Xavier Leleu, Salomon Manier
Bulletin Du Cancer|August 6, 2022
[New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy]Aurélia Chacon, Arthur Bobin, Xavier Leleu
Cancers|April 13, 2023
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple MyelomaAurelia Chacon, Xavier Leleu, Arthur Bobin
Pageof 38